Launch of organs-on-a-chip
Hundreds of micro-organs mimicked on a chip, with minuscule channels that serve as blood vessels. These devices can raise drug development to a new level and reduce animal testing. Leiden researchers and their spin-off company Mimetas are set to launch their ’organs-on-a-chip’, backed by a 200,000 euro subsidy from STW.
'We mimic human organs in a microscopically small space,' explains LACDR researcher and Mimetas co-founder Paul Vulto. 'These organs-on-a-chip can be used to determine the efficacy and toxic side-effects of new medicines better and faster. They provide a unique, novel bridge between traditional laboratory tests and clinical testing in patients. Showing closer resemblance to humans, they have the potential to revolutionise therapeutic drug development and save many laboratory animals at the same time.'
One Mimetas device fits hundreds of micro-organs in which tiny microfluidic channels act as blood vessels. Currently, Mimetas develops its products to help pharmaceutical companies make better medicines at lower costs. Ultimately, Mimetas products will be used to select the best therapy for individual patients, based on direct testing of drugs on diseased cells, so-called personalised medicine.
Mimetas is the result of research and business development efforts by Paul Vulto, Thomas Hankemeier and Bas Trietsch from the University of Leiden and biotech-entrepreneur Jos Joore. Research has been performed within and with support of the Division of Analytical Biosciences and the Netherlands Metabolomics Centre. the Dutch Foundation for Applied Sciences (STW) has awarded Mimetas a subsidy of 200,000 for bringing the 'organs-on-a-chp' to the market.
Mimetas is a Leiden-based microfluidics company focusing on high-throughput biomimetic 3D culture systems for predictive toxicology testing, efficacy screening and personalized therapy. Paul Vulto, Thomas Hankemeier and Jos Joore founded the company in 2011.
The Leiden University Division of Analytical Biosciences (UL-ABS) headed by Prof. Thomas Hankemeier develops innovative analytical tools for metabolomics-driven systems biology in personalised health strategies. The Netherlands Metabolomics Centre (NMC), led by Merlijn van Rijswijk, combines the efforts of individual research groups to expand the Netherlands’ prominent position at the forefront of metabolomic research and technology development.
Health, Life and BioSciences is one of the six themes for research at Leiden University.